about
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.Dexamethasone as a probe for vinorelbine clearance.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.The role of drug-metabolising enzymes in clinical responses to chemotherapy.Clinical pharmacodynamic factors in docetaxel toxicity.Pharmacogenetics and oncology treatment for breast cancer.The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.Pharmacogenetics of membrane transporters: an update on current approaches.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.Level of evidence for therapeutic drug monitoring of taxanes.A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.CYP3A activity: towards dose adaptation to the individual.Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube
P2860
Q33218801-D02B7AC1-9830-4CFE-801E-01B261EF9679Q33829773-D986E242-1806-4B7B-9909-D6F8846088ADQ34974275-8234A1E0-7DA2-4BBF-BE7E-54EC1F74F727Q35051318-87E5B652-1E4E-4647-BD5E-BECF931A790AQ35827137-1F7866F2-CA8C-4949-B085-E5E781570FAEQ36120816-5986462E-181A-42F6-8345-4B11AA27D58DQ36545015-E1F2DE35-F482-4907-994A-3E3CD888678DQ36610962-B99D55FA-B202-450A-A259-3F7E3FFC0A3BQ36719659-485C1E02-B3F0-4032-B743-322B4FD4275FQ37161914-E738D51C-4A6E-44B4-948C-219C786960A0Q37641869-20894BE3-AE08-477E-A52E-23861B8CDCEEQ37684533-76A468AB-C1D4-4A5F-983D-5CB6ED54B21CQ37725978-68952E65-F029-4784-BE84-EF2DCDA28C42Q37788732-8CA9D777-19BE-46ED-B291-5763B831107FQ38347610-5A5A454B-8847-4CCB-A8B7-01D1FF0C4217Q38551666-4BB97AF3-B607-4F4B-A78D-33E8548E7F8CQ38763583-587F3998-F53E-4FFA-8635-A4BF718A8BB8Q41996281-80AD705D-99AF-41F0-A7BD-E14B9DDC44F1
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Dexamethasone as a probe for docetaxel clearance.
@en
Dexamethasone as a probe for docetaxel clearance.
@nl
type
label
Dexamethasone as a probe for docetaxel clearance.
@en
Dexamethasone as a probe for docetaxel clearance.
@nl
prefLabel
Dexamethasone as a probe for docetaxel clearance.
@en
Dexamethasone as a probe for docetaxel clearance.
@nl
P2093
P50
P1476
Dexamethasone as a probe for docetaxel clearance
@en
P2093
Christine Chevreau
Florence Dalenc
Florent Busi
Henri Roché
Isabelle Hennebelle
Thierry Cresteil
Thierry Lafont
P2888
P304
P356
10.1007/S00280-004-0823-0
P577
2004-05-05T00:00:00Z